Pharmaceutical

Carole Tidy has a Diploma in Formulation and an MSc in Pharmaceutical Technology. She is a Member of TOPRA.

Carole has more than 25 years experience in the pharmaceutical industry. She began her career at Fisons Pharmaceuticals, developing and testing new aerosol formulations for asthma. She moved to Merrell Dow (later Marion Merrell Dow) where she worked on the development of a range of oral and parenteral products including Triludan Forte, Perfan and Targocid. She then moved into Regulatory Affairs, where, still at MMD, she held a regulatory compliance role working with manufacturing sites and national MMD regulatory groups to update and unify nationally held licences.

In 1994, Carole moved to Rennie Pharmaceuticals where she held a dual role undertaking both development and regulatory work, in some cases taking a product through from drug substance sourcing to product license. In 1996, Rennie merged with sister company Prova. Carole has gradually moved into an entirely regulatory role and is currently Principal Team Leader, Regulatory for Exova Prova.

Gill Clarke holds a Degree in Pharmacy and a PhD in Pharmaceutics. She is a UK registered Pharmacist and a member of the Industrial Pharmacists Group.

Gill has over 18 years of experience within the pharmaceutical industry and began her career at SmithKline Beecham working on the late phase development of oral and parenteral products including Seroxat and Kytril. She then moved to Eli Lilly where she worked closely with Discovery groups supporting the pharmaceutical development of early stage candidates.

Gill joined Prova in 1999 as Pharmaceutical Development Manager, with responsibilities for the formulation and regulatory groups. She is currently overseeing introduction of a GMP clinical trial manufacturing and packaging facility at the Exova Prova facility in Camberley, Surrey.

Since 2000, Gill has been a regular visiting lecturer for the Professional Development Programme in Pharmaceutical Technology and Quality Assurance at the University of Leeds. She also acts as a pharmaceutical expert in patent litigation cases.

Gill has responsibility for the pharmaceutical development, GMP manufacturing and regulatory groups within Exova Health Sciences.

Mike Scott has over 10 years experience within the pharmaceutical industry and holds a BSc in Pharmaceutical Chemistry.

Mike began his career at Zeneca Pharmaceuticals as a Development Chemist before moving to Napp Pharmaceuticals in 1999 as an Analytical Chemist. He moved to GlaxoWellcome in 2000 on a contract basis before joining Prova in 2000 as an Analytical Chemist.

Mike has progressed to his current position of Senior Analytical Chemist developing a wide range of experience in the analysis of a number of formulations using a range of techniques including HPLC, GC, FT-IR and dissolution. Mike has specific responsibility for the HPLC systems on site and provides end user training and support for the HPLC systems and has gained experience at troubleshooting the systems and methods run on them.

Suzanne Measures has over 15 years experience within the pharmaceutical industry and began her career with Merrell Dow, gaining experience in Quality Control, Clinical Trial Supplies and Pharmaceutical Formulation, including stability co-ordination, before moving on to Development QA/QC with Hoechst Marion Roussel.

Suzanne joined Prova in 1996, progressing to her current role of Principal Team Leader, Stability and Calibration, with responsibility for running the Stability and Calibration Group, managing the stability storage facilities and systems, reference standard systems and calibration schedule. Suzanne has experience in a variety of stability monitoring systems and has coordinated/performed in-house qualification of stability storage facilities for Prova since 1997.

Suzanne designed and planned the stability storage area at Exova Prova's new site, co-ordinated relocation in 2006, and managed subsequent re-qualification of the facilities, ensuring continued compliance with ICH guidelines. More recently, she has been involved in assessing and looking into standardisation of the stability procedures and systems across the Exova Pharma Group.